Intercept's next-gen FXR agonist fails Phase 2 in latest setback for Italian-owned pharma

May 5, 2026 03:01 PM EDT R&D In­ter­cep­t's next-gen FXR ag­o­nist fails Phase 2 in lat­est set­back for Ital­ian-owned phar­ma Kyle LaHucik Biotech Correspondent In­ter­cept Phar­ma­ceu­ti­cals’ at­tempt at cre­at­ing a next-gen­er­a­tion FXR ag­o­nist for cer­tain forms of liv­er in­flam­ma­tion ap­pears to have end­ed. The drug de­vel­op­er’s INT-787 showed “no … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER